Skip to Main Content

A new report from BIO shows just how chaotic the last few years have been for “emerging therapeutic companies” — basically, biotech companies that bring in less than $1 billion in sales.

The report, presented Tuesday at the trade organization’s annual convention, covered acquisitions, IPOs, and venture funding.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!